Wegovy (Semaglutide): GLP-1 Activation Wegovy mimics GLP-1, a hormone your intestines release after you eat
Sun XM, Ren LJ, Bi ZQ, Ji XJ, Zhao QY, Jiang L et al (2018a) Development of a cooperative two-factor adaptive-evolution method to enhance lipid production and prevent lipid peroxidation in Schizochytrium sp
Resveratrol exhibits significant neuroprotective effects by influencing brain metabolism, enhancing mitochondrial function, and regulating autophagy, largely through the activation of AMPK
Cardiometabolic outcomes have taken center stage, with clinical trials tracking secondary and composite endpoints beyond weight loss
Zhang W, Dong XY, Huang R
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
